

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

INSIDE INFORMATION

This announcement is made by Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the subsidiary of the Company, Frontage Holdings Corporation (stock code: 1521, “**Frontage**”), dated October 22, 2026.

The Company notes that trading in the shares of Frontage on The Stock Exchange of Hong Kong Limited has been halted with effect from 9:00 a.m. on October 22, 2026 pending the release of an announcement by Frontage pursuant to the Code on Takeovers and Mergers which contains inside information of Frontage.

The Company will issue further announcement(s) as and when appropriate, and will comply with all applicable requirements under the Listing Rules.

Shareholders and potential investors of the Company should be aware that there is no assurance that the transaction involving Frontage will proceed. Shareholders and potential investors of the Company are advised to exercise caution in dealing in the securities of the Company.

By order of the Board of
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, October 22, 2026

As at the date of this announcement, the executive directors of the Company are Dr. Ye Xiaoping, Ms. Cao Xiaochun, and Mr. Wen Zengyu; the employee director of the Company is Mr. Wu Hao; the independent non-executive directors of the Company are Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Siu Paul Yu Hay.